These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31122098)

  • 1. Does nephrotoxicity develop less frequently when vancomycin is combined with imipenem-cilastatin than with meropenem? A comparative study.
    Hakeam HA; AlAnazi L; Mansour R; AlFudail S; AlMarzouq F
    Infect Dis (Lond); 2019 Aug; 51(8):578-584. PubMed ID: 31122098
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats.
    Nakamura T; Hashimoto Y; Kokuryo T; Inui KI
    Pharm Res; 1998 May; 15(5):734-8. PubMed ID: 9619782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
    Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J
    Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative review of imipenem/cilastatin versus meropenem.
    Salmon-Rousseau A; Martins C; Blot M; Buisson M; Mahy S; Chavanet P; Piroth L
    Med Mal Infect; 2020 Jun; 50(4):316-322. PubMed ID: 32035719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
    Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
    Infection; 1996; 24(6):480-4. PubMed ID: 9007599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats.
    Nakamura T; Kokuryo T; Hashimoto Y; Inui KI
    J Pharm Pharmacol; 1999 Feb; 51(2):227-32. PubMed ID: 10217324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
    Nichols RL; Smith JW; Geckler RW; Wilson SE
    South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
    Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB;
    Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
    Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
    J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus.
    Embil JM; Soto NE; Melnick DA
    Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
    Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
    Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flucloxacillin worsens while imipenem-cilastatin protects against vancomycin-induced kidney injury in a translational rat model.
    Pais GM; Marianski S; Valdez K; Melicor RP; Liu J; Rohani R; Chang J; Tong SYC; Davis JS; Scheetz MH
    Br J Pharmacol; 2024 Mar; 181(5):670-680. PubMed ID: 37696768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
    Kuo BI; Fung CP; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
    Geroulanos SJ
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
    Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
    Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paediatric acute kidney injury induced by vancomycin monotherapy versus combined vancomycin and meropenem.
    Zhang T; Cheng H; Li Y; Dong YZ; Zhang Y; Cheng XL; Wang AM; Dong YL
    J Clin Pharm Ther; 2019 Jun; 44(3):440-446. PubMed ID: 30737860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem.
    Wu Y; Chen K; Shi Z; Wang Q
    Curr Pharm Biotechnol; 2014; 15(8):685-90. PubMed ID: 25051950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group.
    Hamacher J; Vogel F; Lichey J; Kohl FV; Diwok K; Wendel H; Lode H
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():121-33. PubMed ID: 8543488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
    Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
    Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
    Colardyn F; Faulkner KL
    J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.